$TRVI News

Do Trevi Therapeutics’ (TRVI) CORAL Data and GSK’s Exit Reframe Its Chronic Cough Ambitions?

Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting

Trevi Therapeutics Announces Results From Phase 2b CORAL Trial Accepted As Oral Presentation At CHEST 2026 Annual Meeting Of American College Of Chest Physicians

Trevi Therapeutics Q2 2026 Earnings Call Transcript

Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value

Trevi Therapeutics to Participate in Upcoming September Conferences

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform

Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

Trevi Therapeutics Q2 Earnings Call Highlights

Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ...

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript

Trevi Therapeutics Q2 EPS $(0.11), Inline

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Trevi Therapeutics to Participate in Upcoming August Conferences

BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36